Ai-Min Hui Selected Research

ixazomib

1/2017	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
10/2016	The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
9/2016	A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
4/2016	Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
1/2016	Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
9/2015	Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
9/2015	Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
6/2015	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
5/2015	Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
1/2015	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ai-Min Hui Research Topics

Disease

13	Multiple Myeloma 05/2018 - 01/2009
11	Neoplasms (Cancer) 06/2022 - 05/2002
8	Thrombocytopenia (Thrombopenia) 01/2022 - 08/2014
4	Lymphoma (Lymphomas) 10/2016 - 05/2015
4	Peripheral Nervous System Diseases (PNS Diseases) 04/2016 - 08/2014
4	Fatigue 01/2016 - 08/2014
4	Neutropenia 01/2016 - 08/2014
3	Exanthema (Rash) 04/2016 - 08/2014
3	Diarrhea 01/2016 - 08/2014
2	Chronic Renal Insufficiency 09/2022 - 06/2022
2	COVID-19 06/2022 - 01/2021
2	Immunoglobulin Light-chain Amyloidosis 01/2017 - 01/2015
2	Nausea 08/2014 - 08/2014
2	Breast Neoplasms (Breast Cancer) 06/2008 - 12/2004
2	Glioma (Gliomas) 04/2006 - 12/2004
2	Hepatocellular Carcinoma (Hepatoma) 02/2005 - 11/2004
1	Anemia 06/2022
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Hematuria 01/2022
1	Proteinuria 01/2022
1	Hemorrhage 01/2022
1	Hyperbilirubinemia 01/2022
1	Liver Diseases (Liver Disease) 01/2022
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 09/2016
1	Disease Progression 04/2016
1	Chromosome Aberrations (Chromosome Abnormalities) 04/2016
1	Hematologic Neoplasms (Hematological Malignancy) 06/2015
1	Skin Diseases (Skin Disease) 12/2014
1	Vomiting 08/2014
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2009
1	Necrosis 06/2008
1	Neoplasm Metastasis (Metastasis) 06/2008
1	Brain Injuries (Brain Injury) 04/2006
1	Carcinoma (Carcinomatosis) 09/2002

Drug/Important Bio-Agent (IBA)

13	ixazomibIBA 01/2017 - 08/2014
13	Proteasome InhibitorsIBA 01/2017 - 01/2009
7	Pharmaceutical PreparationsIBA 01/2022 - 12/2004
4	Dexamethasone (Maxidex)FDA LinkGeneric 05/2018 - 12/2014
4	Bortezomib (Velcade)FDA Link 01/2017 - 01/2009
4	Lenalidomide (CC 5013)FDA Link 04/2016 - 08/2014
3	Proteasome Endopeptidase Complex (Proteasome)IBA 06/2015 - 01/2009
2	ferric pyrophosphateIBA 09/2022 - 06/2022
2	Citric Acid (Citrate)FDA LinkGeneric 09/2022 - 06/2022
2	mRNA VaccinesIBA 06/2022 - 01/2021
2	VaccinesIBA 06/2022 - 01/2021
2	Messenger RNA (mRNA)IBA 01/2021 - 11/2004
2	Proteins (Proteins, Gene)FDA Link 02/2005 - 11/2004
1	IronIBA 06/2022
1	Cancer VaccinesIBA 06/2022
1	RNA (Ribonucleic Acid)IBA 06/2022
1	pretomanidIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 01/2022
1	avatrombopagIBA 01/2022
1	Uric Acid (Urate)IBA 01/2022
1	ErbB Receptors (EGF Receptor)IBA 01/2022
1	pomalidomideIBA 05/2018
1	isatuximabIBA 05/2018
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 01/2017
1	CreatinineIBA 09/2016
1	Amyloid (Amyloid Fibrils)IBA 01/2015
1	carfilzomibIBA 08/2014
1	Thalidomide (Thalomid)FDA Link 08/2014
1	marizomibIBA 08/2014
1	Boronic AcidsIBA 01/2009
1	PolymersIBA 06/2008
1	arginyl-glycyl-aspartic acidIBA 06/2008
1	AH 111585IBA 06/2008
1	LigandsIBA 06/2008
1	Peptides (Polypeptides)IBA 06/2008
1	IntegrinsIBA 06/2008
1	Integrin alphaVIBA 06/2008
1	Integrin beta3 (GPIIIa)IBA 06/2008
1	Stem Cell FactorIBA 04/2006
1	Trefoil FactorsIBA 02/2005
1	Trefoil Factor-3IBA 02/2005
1	AntigensIBA 02/2005
1	Tamoxifen FDA LinkGeneric 12/2004
1	Selective Estrogen Receptor Modulators (SERM)IBA 12/2004
1	CC-8490IBA 12/2004
1	NF-kappa B (NF-kB)IBA 12/2004
1	Estrogen ReceptorsIBA 12/2004
1	Ki-67 Antigen (Ki 67 Antigen)IBA 09/2002
1	Cyclin D1IBA 09/2002
1	Cyclin EIBA 09/2002
1	Tumor Biomarkers (Tumor Markers)IBA 05/2002

Therapy/Procedure

6	Therapeutics 06/2022 - 09/2002
2	Renal Dialysis (Hemodialysis) 09/2022 - 06/2022
1	Platelet Transfusion (Blood Platelet Transfusions) 01/2022